Anavex Confirms Data for Phase 2a Alzheimer’s Trial for ANAVEX 2-73

NEW YORK, Nov. 11, 2015  -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (AVXL) confirms the information in the November 9, 2015 press release announcing positive safety and cognitive efficacy data from the Phase 2a Alzheimer’s trial for ANAVEX 2-73.

Anavex confirms that there has been no change with regards to our science, data or the fundamentals of our Company. We remain dedicated to advancing ANAVEX 2-73 through the ongoing Phase 2a trial and to reporting new data to investors as it becomes available.

Anavex confirms the data included in its news release dated November 9, 2015.

Bellicum Pharmaceuticals Reports Third Quarter 2015 Financial Results and Recent Program Updates

Pediatric patients with beta thalassemia, SCID, and Wiskott-Aldrich Syndrome are disease-free following haplo transplant with BPX-501 T cells
Additional details of ongoing BPX-501 trial and adoptive T cell programs to be presented at ASH 2015

HOUSTON-- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for cancers and orphan inherited blood disorders, today reported financial results for the third quarter of 2015 and provided an update on recent developments.

“During the third quarter we continued to make good progress in the advancement of our stem cell transplant, CAR-T and TCR programs,” said Tom Farrell, President and Chief Executive Officer of Bellicum.

Astellas to Acquire Ocata Therapeutics

- New Step Forward in Ophthalmology with Cell Therapy Approach -

TOKYO and MASSACHUSETTS, Nov. 9, 2015 -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, "Astellas") and Ocata Therapeutics, Inc. (NASDAQ: OCAT, President and CEO: Paul Wotton, "Ocata"), a biotechnology company focused on the research and development of new therapies in the field of regenerative medicine, primarily cell therapy addressing unmet medical needs in ophthalmology patients, announced today that they have entered into a definitive agreement. Under the agreement, Astellas will acquire Ocata through Laurel Acquisition Inc., a wholly-owned subsidiary of Astellas US Holding, Inc. ("Laurel"). The boards of directors of both Astellas and Ocata have unanimously approved the agreement.